Presentation is loading. Please wait.

Presentation is loading. Please wait.

1 SAPA-GP Webinar Program A Professional Training Tool for SAPA Members Non-members are Welcome to Participate SAPA-GP Webinar Program A Professional Training.

Similar presentations


Presentation on theme: "1 SAPA-GP Webinar Program A Professional Training Tool for SAPA Members Non-members are Welcome to Participate SAPA-GP Webinar Program A Professional Training."— Presentation transcript:

1 1 SAPA-GP Webinar Program A Professional Training Tool for SAPA Members Non-members are Welcome to Participate SAPA-GP Webinar Program A Professional Training Tool for SAPA Members Non-members are Welcome to Participate January, 2013 Introduction of Early Drug Development Dr. Sean Zhang, MD, FCP Medical Director, Bristol-Myers Squibb (BMS) February, 2013 Late Stage of Clinical Drug Development, e.g., Ph 2b/3 Studies/Strategies Dr. Joan Shen, MD. PhD. Senior Medical Director, China Clinical Lead, PCBU Pfizer Inc. April, 2013 Regulatory Requirements for the CTA of Multinational Clinical Trials in China Dr. Cathleen CHAN/ 陈明 Regulatory Director, Sanofi R&D China

2 2 Regulatory Requirements for the CTA of Multinational Clinical Trials in China April. 16 th, 2013 SAPA-GP Webinar Program Cathleen CHAN, MD. Regulatory Director, Regulatory R&D China, GRA Sanofi R&D

3 3 Background Dr. Chan is a physician. She starts her career in the sales and marketing in the pharmaceutical and medical device industry in China Dr. Chan has worked as the regional head in the sales and marketing for the North of China, director in regulatory and government affairs for China and Asia Dr. Chan gained her broad regulatory experience in Servier and Sanofi, where she is the head in regulatory, responsible for IND, NDA and LCM for Asia and China Dr. Chan has been very devoted to Multinational Clinical Trial Applications for global and regional clinical trials with the CFDA in the last 10 years Dr. Chan leads Asian regional and China R&D regulatory team in regulatory strategy and operation for Sanofi, success in shorting the CTA review timeline by improving internal practice and collaborating with academy, associations in China

4 4 Presentation Outlines: General Regulatory Requirements for the Multinational Clinical Trials Hurdles of CTA for the Multinational Clinical Trials for IND in China Description of China CTA Package contents – CFDA requirement How to Prepare an China CTA Package Based on EU/IMPD (Investigational Medical Product Document) or US/IND package


Download ppt "1 SAPA-GP Webinar Program A Professional Training Tool for SAPA Members Non-members are Welcome to Participate SAPA-GP Webinar Program A Professional Training."

Similar presentations


Ads by Google